Abstract
Sepsis, an amplified immune response to systemic infection that leads to life-threatening organ dysfunction, affects >125,000 people/ day worldwide with 20% mortality. Modest therapeutic progress for sepsis has been made, in part because of the lack of therapeutic translatability between mouse-based experimental models and humans. One potential reason for this difference stems from the extensive use of immunologically naive specific pathogen-free mice in preclinical research. To address this issue, we used sequential infections with well-defined BSL-2 pathogens to establish a novel immune-experienced mouse model (specific pathogen experienced [SPexp]) to determine the extent to which immunological experience and/or inflammation influences the host capacity to respond to subsequent infections, including sepsis. Consistent with their immunological experience, SPexp inbred or outbred mice had significant changes in the composition and activation status of multiple leukocyte populations known to influence the severity of cecal ligation and puncture–induced sepsis. Importantly, by varying the timing of sepsis induction, we found the level of basal inflammation controls sepsis-induced morbidity and mortality in SPexp mice. In addition, although a beneficial role of NK cells in sepsis was recently demonstrated in specific pathogen-free mice, NK cell depletion before cecal ligation and puncture induction in SPexp mice lead to diminished mortality, suggesting NK cells may have beneficial or detrimental roles in the response to septic insult dependent on host immune status. Thus, data highlight the importance of utilizing immune-experienced models for preclinical studies to interrogate the cellular/molecular mechanism(s) that could be therapeutically exploited during severe and dysregulated infection-induced inflammatory responses, such as sepsis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 528-542 |
| Number of pages | 15 |
| Journal | ImmunoHorizons |
| Volume | 6 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2022 |
Bibliographical note
Funding Information:Received for publication June 30, 2022. Accepted for publication June 30, 2022. Address correspondence and reprint requests to: Dr. Vladimir P. Badovinac, Department of Pathology, University of Iowa, 3-550 BSB, 51 Newton Road, Iowa City, IA 52242. E-mail address: [email protected] ORCIDs: 0000-0003-1517-8541 (R.R.B.); 0000-0002-3107-3961 (I.J.J.); 0000-0001-7266-2802 (J.T.H.); 0000-0002-7205-9859 (T.S.G.); 0000-0003-3180-2439 (V.P.B.). This work was supported by National Institutes of Health Grants GM134880 (to V.P.B.), AI114543 (to V.P.B. and J.T.H.), AI151183 (to V.P.B. and J.T.H.), AI42767 (to J.T.H.), R35GM140881 (to T.S.G.), and T32AI007485 (to R.R.B. and I.J.J.); The Holden Comprehensive Cancer Center at The University of Iowa and its National Cancer Institute Award P30CA086862 (to V.P.B); and Veterans Administration Merit Review Award I01BX001324 (to T.S.G.). Abbreviations used in this article: CLP, cecal ligation and puncture; CoH, cohoused; EAE, experimental autoimmune encephalomyelitis; IAV, influenza A virus; LCMV-Arm, lymphocytic choriomeningitis virus–Armstrong; MCMV, murine CMV; PBL, peripheral blood leukocyte; PR8, Puerto Rico/8/34; SPexp, specific pathogen experienced; SPfree, specific pathogen-free. The online version of this article contains supplemental material. This article is distributed under the terms of the CC BY 4.0 Unported license.
Publisher Copyright:
Copyright © 2022 The Authors.
Fingerprint
Dive into the research topics of 'Inflammation Controls Susceptibility of Immune-Experienced Mice to Sepsis'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS